Citius Oncology, Inc.
NASDAQ:CTORDrug Manufacturers - General
+$0.03 today
- Market cap
- $51.83M
- Beta
- 3.42
- P/E (TTM)
- -1.6
- EPS (TTM)
- -$0.42
Volume 0.15M
Average 0.12M
CTOR Other Non-current Assets
Long-term assets not reported separately.
Citius Oncology, Inc.NASDAQ: CTOR
Other Non-current Assets · Q2 FY2026 · quarter ended Mar 2026
Other non-current assets falls 99.8% from a year ago
Other non-current assets stood at $169.25K at the end of Q2 FY2026, down 99.8% from a year earlier and down 99.8% from the prior quarter. Over 3 fiscal years it compounded at +22.4% a year.
Context
- Other non-current assets amounted to 0.2% of total assets at the end of Q2 FY2026, down 80.1 pp from a year earlier.
- Other non-current assets increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether other non-current assets keeps falling in the next quarterly balance sheet after a -99.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Non-current Assets history
USD · from the balance sheet
- Latest · FY2025
- 73.4M USD
- Year-over-year change
- +0.0%
- 3-year CAGR
- +22.4%
| Period | Period end | Other Non-current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 73.4M | +0.0% |
| FY2024 | 2024-09-30 | 73.4M | +83.5% |
| FY2023 | 2023-09-30 | 40M | +0.0% |
| FY2022 | 2022-09-30 | 40M | — |
Other Non-current Assets vs competitors
How CTOR compares with its peers on the latest reported figures
- CTOR's Mar 2026 other non-current assets of $169.25K is the 8th highest of the 10 companies compared; the peer median is $2M.
- Its year-over-year change of -99.8% is the lowest of 10, against a peer median of +0.0%.
- Other non-current assets amounts to 0.2% of total assets for CTOR, versus a peer median of 3.0%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $145.99M | +122582.4% | +519.7% | 49.7% | |
| Mar 2026 | $10.05M | -1.7% | -57.4% | 3.5% | |
| Mar 2026 | $2.58M | -46.1% | -4.4% | 0.5% | |
| Mar 2026 | $2.55M | -25.3% | +82.4% | 3.9% | |
| Mar 2026 | $2M | +1038.1% | +61.9% | 3.0% | |
| Mar 2026 | $1.84M | +6.5% | +16.7% | 2.1% | |
ACTUActuate Therapeutics Inc | Mar 2026 | $391.84K | +67.1% | — | 4.4% |
CTORCitius Oncology, Inc. | Mar 2026 | $169.25K | -99.8% | +22.4% | 0.2% |
| Mar 2026 | $153K | +0.0% | -75.3% | 0.3% | |
| Mar 2026 | $31K | -0.0% | -85.6% | 0.0% | |
| Peer median (excluding CTOR) | $2M | +0.0% | +6.1% | 3.0% | |
Competitors are the stored peer set for CTOR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Citius Oncology, Inc.
NASDAQ:CTOR
Intrinsic Alpha fair value
Locked
Current Price
$0.56
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.